|Day's Range||34.3000 - 34.6700|
|52 Week Range||25.2500 - 36.8200|
|PE Ratio (TTM)||24.55|
|Dividend & Yield||1.03 (3.00%)|
|1y Target Est||N/A|
Incyte stock popped to a month-high Thursday after its immuno-oncology drug proved effective in matchups with Merck's Keytruda and Bristol's Opdivo.
Pivotal trial results for Merck & Co Inc's immunotherapy drug Keytruda show that it lengthened survival by three months, or nearly 40 percent, for patients with advanced bladder cancer who had stopped responding to chemotherapy. The data, to be presented next month at a meeting of the American Society of Clinical Oncology, follow last week's announcement that rival drug Tecentriq, from Roche Holding AG , did not improve survival when used as a second-line treatment for bladder cancer in a trial. The Merck drug is awaiting U.S. Food and Drug Administration approval, but Tecentriq was approved by the agency last year, contingent on verification of its clinical benefit.